Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 165.72 8.3 (5.27%) Market Cap: 20.96 Bil Enterprise Value: 19.89 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 67/100

Alnylam Pharmaceuticals Inc at SVB Leerink Global Healthcare Conference (Virtual) Transcript

Feb 25, 2021 / 04:20PM GMT
Release Date Price: $146.59 (-3.30%)
Mani Foroohar
SVB Leerink LLC, Research Division - MD of Genetic Medicines & Senior Research Analyst

Good morning, and we're continuing actually the presentations here at this year's Global Healthcare Conference. I'm Mani Foroohar, a senior analyst covering drug medicines here at SVB Leerink. I'm very fortunate to have Yvonne Greenstreet joining us from Alnylam. Yvonne, how are you doing today?

Yvonne L. Greenstreet
Alnylam Pharmaceuticals, Inc. - President & COO

Yes. Good morning, everybody. Delighted to be here. We had a year of incredible performance at Alnylam in 2020. Commercial performance was great, delivered $306 million of global net product sales from ONPATTRO with 1,350 patients. And we're pleased with our innovative approaches to access. We've got 98% coverage of lives in the U.S.

GIVLAARI also did really well. First full year sales, $55 million, 200 patients. And again, great access, 94% in the U.S., but also sales in Germany, ATU in France and some other name patient sales

And OXLUMO was launched. It got approved in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot